SI1869056T1 - Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati - Google Patents

Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati

Info

Publication number
SI1869056T1
SI1869056T1 SI200630886T SI200630886T SI1869056T1 SI 1869056 T1 SI1869056 T1 SI 1869056T1 SI 200630886 T SI200630886 T SI 200630886T SI 200630886 T SI200630886 T SI 200630886T SI 1869056 T1 SI1869056 T1 SI 1869056T1
Authority
SI
Slovenia
Prior art keywords
thiazoloy4
amino
substituted
novel
pyrimidine derivatives
Prior art date
Application number
SI200630886T
Other languages
English (en)
Slovenian (sl)
Inventor
Gunnar Nordvall
Colin Ray
Tobias Rein
Daniel Sohn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1869056T1 publication Critical patent/SI1869056T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI200630886T 2005-04-06 2006-04-03 Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati SI1869056T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06
EP06717078A EP1869056B1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-ý1,3¨thiazoloý4,5-d¨pyrimidine derivatives
PCT/SE2006/000399 WO2006107258A1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Publications (1)

Publication Number Publication Date
SI1869056T1 true SI1869056T1 (sl) 2011-02-28

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630886T SI1869056T1 (sl) 2005-04-06 2006-04-03 Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati

Country Status (30)

Country Link
US (2) US7947693B2 (OSRAM)
EP (1) EP1869056B1 (OSRAM)
JP (1) JP5165553B2 (OSRAM)
KR (1) KR101335055B1 (OSRAM)
CN (1) CN101193897B (OSRAM)
AR (1) AR055890A1 (OSRAM)
AT (1) ATE487727T1 (OSRAM)
AU (1) AU2006231836B2 (OSRAM)
BR (1) BRPI0609738A2 (OSRAM)
CA (1) CA2604017C (OSRAM)
CY (1) CY1111316T1 (OSRAM)
DE (1) DE602006018124D1 (OSRAM)
DK (1) DK1869056T3 (OSRAM)
ES (1) ES2354450T3 (OSRAM)
HR (1) HRP20110047T1 (OSRAM)
IL (1) IL185912A0 (OSRAM)
MX (1) MX2007012060A (OSRAM)
NO (1) NO20075603L (OSRAM)
NZ (1) NZ561460A (OSRAM)
PL (1) PL1869056T3 (OSRAM)
PT (1) PT1869056E (OSRAM)
RS (1) RS51581B (OSRAM)
RU (1) RU2419623C2 (OSRAM)
SA (1) SA06270072B1 (OSRAM)
SI (1) SI1869056T1 (OSRAM)
TW (1) TW200714605A (OSRAM)
UA (1) UA90707C2 (OSRAM)
UY (1) UY29454A1 (OSRAM)
WO (1) WO2006107258A1 (OSRAM)
ZA (1) ZA200708187B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
RU2437889C2 (ru) * 2006-09-29 2011-12-27 Астразенека Аб НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
PL2254870T3 (pl) 2008-03-07 2016-07-29 Acraf Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
GEP20135913B (en) 2008-03-07 2013-08-26 Acraf 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
KR20150129698A (ko) 2013-03-12 2015-11-20 에자이 알앤드디 매니지먼트 가부시키가이샤 피롤리딘-3-일 아세트산 유도체의 염 및 그의 결정
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
US20180222922A1 (en) * 2015-06-08 2018-08-09 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
WO2018204370A1 (en) 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
CN120077035A (zh) 2022-10-19 2025-05-30 阿斯利康(瑞典)有限公司 作为cx3cr1的调节剂的2,4,6-三取代的1,3,5-三嗪
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (OSRAM) 1955-01-03
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
ATE214704T1 (de) * 1997-07-18 2002-04-15 Hoffmann La Roche 5h-thiazolo(3,2-a)pyrimidinderivate
WO1999051608A1 (en) 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
AU2881399A (en) 1998-05-01 1999-11-23 Eli Lilly And Company N1-modified glycopeptides
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
DE60101372T2 (de) 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2003299795A1 (en) * 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
JP2008524186A (ja) * 2004-12-17 2008-07-10 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
RS51581B (sr) 2011-08-31
TW200714605A (en) 2007-04-16
HRP20110047T1 (hr) 2011-03-31
DK1869056T3 (da) 2011-02-07
RU2007140551A (ru) 2009-05-20
NZ561460A (en) 2010-12-24
UY29454A1 (es) 2006-11-30
NO20075603L (no) 2008-01-04
AR055890A1 (es) 2007-09-12
ATE487727T1 (de) 2010-11-15
IL185912A0 (en) 2008-01-06
AU2006231836A1 (en) 2006-10-12
EP1869056A1 (en) 2007-12-26
PL1869056T3 (pl) 2011-04-29
AU2006231836B2 (en) 2010-07-15
BRPI0609738A2 (pt) 2011-10-18
ES2354450T3 (es) 2011-03-15
HK1118556A1 (en) 2009-02-13
CA2604017A1 (en) 2006-10-12
US7947693B2 (en) 2011-05-24
JP5165553B2 (ja) 2013-03-21
DE602006018124D1 (de) 2010-12-23
CA2604017C (en) 2012-03-06
EP1869056A4 (en) 2010-02-17
UA90707C2 (en) 2010-05-25
CY1111316T1 (el) 2015-08-05
JP2008535835A (ja) 2008-09-04
PT1869056E (pt) 2011-01-13
EP1869056B1 (en) 2010-11-10
MX2007012060A (es) 2007-12-13
KR20080004483A (ko) 2008-01-09
CN101193897A (zh) 2008-06-04
CN101193897B (zh) 2010-12-01
RU2419623C2 (ru) 2011-05-27
SA06270072B1 (ar) 2009-02-07
US20080214578A1 (en) 2008-09-04
US20110092519A1 (en) 2011-04-21
KR101335055B1 (ko) 2013-12-02
WO2006107258A1 (en) 2006-10-12
US9440992B2 (en) 2016-09-13
ZA200708187B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
IL185912A0 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
ZA200705040B (en) 2,4 (4,6) pyrimidine derivatives
ZA200805294B (en) Pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
IL181386A0 (en) Pyrimidine derivatives
GB0415364D0 (en) Pyrimidine derivatives
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
IL186661A0 (en) Heterocyclic antiviral compounds
GB0525080D0 (en) Pyrimidine derivatives
AP2005003403A0 (en) Substituted pyrimidinones.
ZA200804301B (en) 1,5-substituted indol-2-yl amide derivatives
GB0525083D0 (en) Pyrimidine derivatives
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
SMAP200800029A (it) 2-ammino-7,8-diidro-6h.pirido[4,3-d]pirimidin-5-oni
GB0415367D0 (en) Pyrimidine derivatives
IL179914A0 (en) Pyrimidine derivatives
AP2281A (en) Novel compounds.
GB0525081D0 (en) Pyrimidine derivatives
PL1644343T3 (pl) Pochodne 5-podstawionego chinazolinonu
AP2157A (en) 2-substituted pyrimidines.
IL186221A0 (en) Crystalline rosuvastatin intermediate
ZA200700162B (en) Novel heterocyclic compounds
TWI315670B (en) Substituted aryl 1,4-pyrazine derivatives
IL186226A0 (en) (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines